Friday, June 12, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 124 of 1,261
  1. US 11958910

    Bispecific antigen binding molecules that bind HER2, and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  2. US 11957677

    Cancer treatment using FGFR inhibitors and PLK1 inhibitors

    Cardiff Oncology, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  3. US 11958845

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  4. US 11958850

    Heteroaryl compounds for kinase inhibition

    Takeda Pharmaceutical Company Limited Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  5. US 11958908

    Compositions and methods for the depletion of CD117+ cells

    CRISPR THERAPEUTICS AG Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  6. US 11958849

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  7. US 11958893

    Methods for modulating an immune response

    Cue Biopharma, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  8. US 11958909

    Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use

    Sutro Biopharma, Inc. Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  9. US 11958862

    Compounds and compositions and uses thereof

    PGI Drug Discovery LLC Β· Granted Apr 16, 2024 Β· Expires Apr 11, 2044

    granted
  10. EP 4350345

    VERFAHREN ZUR VORHERSAGE, ERKENNUNG UND REDUZIERUNG VON ASPEZIFISCHER PROTEININTERFERENZ IN TESTS MIT VARIABLEN IMMUNGLOBULIN-EINZELDOMΓ„NEN

    ABLYNX NV [BE] Β· Granted Apr 10, 2024 Β· Expires Apr 5, 2044

    granted
  11. US 11952419

    Reagents and methods for treating cancer and autoimmune disease

    UNIVERSITY OF CONNECTICUT Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  12. US 11951121

    Compositions and methods for treating Huntington's disease

    VOYAGER THERAPEUTICS, INC. Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  13. US 11951227

    Nanofiber structures and methods of use thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  14. US 11952362

    Compositions and methods for treating epigenetic disease

    The Regents of the University of California Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  15. US 11952600

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  16. US 11952374

    Bicyclic compounds

    Aligos Therapeutics, Inc. Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  17. US 11951100

    Formulations of RBP4 inhibitors and methods of use

    Belite Bio, Inc Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  18. US 11952376

    Substituted amino acids as integrin inhibitors

    Pliant Therapeutics, Inc. Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  19. US 11951159

    Cattle fever tick-infestation vaccines and uses thereof

    The United States of America, as represented by the Secretary of Agriculture Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  20. US 11952429

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  21. US 11951206

    Cell housing device

    Vertex Pharmaceuticals Incorporated Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  22. US 11951176

    Stabilization of glucagon by trehalose glycopolymer nanogels

    The Regents of the University of California Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  23. US 11952427

    Anti-CD40 antibodies and uses thereof

    CytomX Therapeutics, Inc. Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted
  24. US 11952352

    Ras inhibitors

    Revolution Medicines, Inc. Β· Granted Apr 9, 2024 Β· Expires Apr 4, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.